WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 530613
Description: VU0359595, also known as ML-270 and CID-53361951, is an inhibitor of PLD1 (IC50 = 3.7 nM). Downregulation of PLD1 and exposure to the PLD1 inhibitor VU0359595 attenuated PLD activity and strongly reduced the mitogenic activity of serum and IGF-1. Phospholipase D is a target for inhibition of astroglial proliferation by ethanol.
MedKoo Cat#: 530613
Chemical Formula: C25H29BrN4O2
Exact Mass: 496.1474
Molecular Weight: 497.437
Elemental Analysis: C, 60.36; H, 5.88; Br, 16.06; N, 11.26; O, 6.43
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: ML-270, ML 270, ML270, VU0359595, VU-0359595, VU 0359595, CID-53361951, CID53361951, CID 53361951
IUPAC/Chemical Name: (1R,2R)-N-[(1S)-2-[4-(5-bromo-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]-1-methylethyl]-2-phenyl-cyclopropanecarboxamide
InChi Key: JSVNNLRZCJAYTQ-ORYQWCPZSA-N
InChi Code: InChI=1S/C25H29BrN4O2/c1-16(27-24(31)21-14-20(21)17-5-3-2-4-6-17)15-29-11-9-19(10-12-29)30-23-8-7-18(26)13-22(23)28-25(30)32/h2-8,13,16,19-21H,9-12,14-15H2,1H3,(H,27,31)(H,28,32)/t16-,20-,21+/m0/s1
SMILES Code: O=C([C@H]1[C@H](C2=CC=CC=C2)C1)N[C@@H](C)CN3CCC(N4C5=CC=C(Br)C=C5NC4=O)CC3
Appearance: White to off-white solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 497.437 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Chaves-Moreira D, de Moraes FR, Caruso ÍP, Chaim OM, Senff-Ribeiro A, Ullah A, da Silva LS, Chahine J, Arni RK, Veiga SS. Potential Implications for Designing Drugs Against the Brown Spider Venom Phospholipase-D. J Cell Biochem. 2017 Apr;118(4):726-738. doi: 10.1002/jcb.25678. Epub 2016 Oct 26. PubMed PMID: 27563734.
2: Burkhardt U, Beyer S, Klein J. Role of phospholipases D1 and 2 in astroglial proliferation: effects of specific inhibitors and genetic deletion. Eur J Pharmacol. 2015 Aug 15;761:398-404. doi: 10.1016/j.ejphar.2015.05.004. Epub 2015 May 9. PubMed PMID: 25967349.
3: Burkhardt U, Wojcik B, Zimmermann M, Klein J. Phospholipase D is a target for inhibition of astroglial proliferation by ethanol. Neuropharmacology. 2014 Apr;79:1-9. doi: 10.1016/j.neuropharm.2013.11.002. Epub 2013 Nov 19. PubMed PMID: 24262632.